Ensysce Biosciences' Chief Medical Officer Speaks at FDA Hearing on Psychedelic Drugs
News related to:Ensysce Biosciences Inc · 1 min read
Ensysce Biosciences, a clinical-stage biotechnology company, has announced that its Chief Medical Officer, Richard Langford, will present at an FDA public hearing on the potential future therapeutic use of psychedelic drugs.
The FDA is convening the hearing in collaboration with federal partners to gather feedback and perspectives on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings. This event supports the implementation of Executive Order 14401, which aims to accelerate the research, review, and approval of psychedelic drugs for the treatment of serious mental health conditions.
Ensysce Biosciences recently announced the acquisition of Cy Biopharma on August 6, 2026. The company is developing novel neuroplastogenic therapies that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. Additionally, Ensysce is working on a new class of highly novel opioids for the treatment of severe pain, with a focus on minimizing the risk of drug abuse and overdose.
Dr. Lynn Kirkpatrick, Ensysce Biosciences' Chief Executive Officer, expressed enthusiasm about Langford's participation in the hearing.
Kirkpatrick further emphasized Ensysce's commitment to shaping the path to patients, highlighting the company's dedication to advancing therapies that could provide relief for those suffering from complex pain conditions.
Ensysce Biosciences is developing a range of innovative therapies that address chronic pain and mental health disorders. The company believes that its approach, which includes the use of psychedelics, could offer new hope to patients who have not found relief through traditional treatments. The FDA hearing is a significant milestone in the regulatory process, and Ensysce's participation underscores its commitment to innovation and patient care.
The hearing is part of a broader effort to accelerate the development and approval of psychedelic drugs for serious mental health conditions. Ensysce Biosciences' involvement in this process is seen as a critical step in advancing the field and bringing new treatments to patients in need.